The Priority Review

Tag

Stream

353 stories ยท page 10 of 30

Stories

  1. Clinical trials

    Ascendis registers Phase 3 trial of navepegritide in hypochondroplasia

    The study, led by Ascendis Pharma A/S, plans to enroll 81 children and adolescents with hypochondroplasia and has a planned start date of November 2026. It is a randomized, double-blind, placebo-controlled trial that plans to reach primary completion in October 2028.

  2. Clinical trials

    Novartis posts results of Phase 3 KLU156 trial in uncomplicated P. Falciparum malaria

    The study, led by Novartis Pharmaceuticals, enrolled 1720 participants and completed enrollment on March 7, 2024, with primary completion on June 27, 2025. Results were first posted on ClinicalTrials.gov on November 4, 2026, confirming the efficacy, safety and tolerability of KLU156 compared with Coartem in adults and children.

  3. Clinical trials

    Takeda posts results of Phase 3 TAK-279 study in psoriasis

    The study enrolled 18 participants and completed primary data collection on October 17, 2025. Results were first posted on ClinicalTrials.gov on November 4, 2026.

  4. Clinical trials

    Alexion posts results of Phase 3 ravulizumab trial in HSCT-TMA

    The study enrolled 148 participants and completed primary data collection on September 19, 2025. Results were first posted on ClinicalTrials.gov on November 4, 2026.

  5. Clinical trials

    Novo Nordisk posts results of Phase 3 KBP-5074 trial in uncontrolled hypertension and CKD

    The study enrolled 666 participants and began on November 5, 2021, with primary completion on January 30, 2024. The trial was terminated and the results were first posted on ClinicalTrials.gov on November 4, 2026.

  6. Clinical trials

    Cognixion enrolls participants in NIH-funded BCI study for ALS

    Cognixion Corporation announced it is now enrolling 30 adults with ALS in the CHOICE study, a 12-week trial comparing its investigational brain-computer interface with eye-tracking devices. The study is supported by the National Institute on Deafness and Other Communication Disorders and is registered on ClinicalTrials.gov as NCT07871071.

  7. Clinical trials

    Minghui and ASKA enter exclusive license for MHB018A in Japan

    Minghui Pharmaceutical and ASKA Pharmaceutical announced an exclusive license agreement for the development and commercialization of MHB018A in Japan, with ASKA receiving rights to seek regulatory approval and commercialize the antibody. The agreement includes an upfront payment of USD 110 million and potential milestone payments of up to USD 330 million, plus tiered royalties up to mid-30 % on net sales in Japan.

  8. Policy

    WuXi Biologics receives double honors at 2026 HERA for ESG reporting and environmental excellence

    WuXi Biologics (2269.HK) won Best ESG Report (Large-Cap) and Excellence in Environmental Positive Impact at the ninth Hong Kong ESG Reporting Awards, becoming the only pharmaceutical company to receive a Grand Award. The company said the awards recognize its ongoing commitment to transparent ESG disclosure and measurable environmental progress across its global operations.

  9. Policy

    Samsung Biologics achieves 'Negligible Risk' rating in Sustainalytics ESG assessment

    Samsung Biologics received an ESG Risk Rating score of 9.0, advancing from its previous 'Low Risk' rating to 'Negligible Risk,' the lowest of five risk categories. The result places the company among the top 0.5% of companies assessed in the pharmaceuticals industry.

  10. Clinical trials

    Thryv Therapeutics announces $30 million financing to launch ASPIRE-HF study

    The company secured $30 million Series B financing led by InClin, Inc. to fund the Phase 2a ASPIRE-HF study in heart failure with reduced ejection fraction and QTc prolongation, which opens for enrollment in early 2027. Wave II, a Phase 2/3 study of THRV-1268 in Long QT Syndrome, has completed enrollment of its first efficacy cohort, with data expected in early 2027.

  11. Clinical trials

    Xtalks hosts webinar on smarter site selection for early-phase trials

    The webinar, scheduled for Tuesday, November 17, 2026 at 11am EST, will explore how early-phase biotech teams can improve enrollment predictability by integrating recruitment into study design and site selection. Speakers include Chris Morris of PPD, Irina Strachkova of Patient First Digital Solutions, and Dr. Lukasz Wiech of Trialmed.

  12. Clinical trials

    Hutchmed registers Phase III trial of HMPL-306 in postoperative residual or recurrent grade 2 glioma

    The study plans to enroll 210 participants and plans to begin in November 2026, with primary completion projected for March 2032. It is a randomized, double-blind, placebo-controlled multicenter Phase III trial evaluating HMPL-306 tablet safety and efficacy.